In this segment from Market Foolery, Chris Hill is joined by Bill Barker and Jim Gillies as they consider the growing challenges at Valeant Pharmaceuticals (NYSE: VRX), which has seen scandal after scandal tank its stock price and reputation. The question remains: Does Valeant still have value, or a future, as a public company.
A full transcript follows the video.